Navigation Links
Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:10/20/2008

hnology partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (File No. 333-145638), Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.

BCRXW


'/>"/>
SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
2. Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
3. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
6. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
7. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
8. BioXcel Forms a Corporate Advisory Board for Its Next Phase of Growth
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 “2014 Deep Research ... Industry” is a professional and in-depth research ... introduces Polyurethane Resin basic information, including its ... and industry overview. This research covers the ... as well as global industry analysis covering ...
(Date:7/31/2014)... see through organs and even the entire body to ... cellular structures has been a long-time dream of biologists. ... 31st in the journal Cell has now ... making opaque organs, bodies, and human tissue biopsies transparent, ... protocols could pave the way for a better understanding ...
(Date:7/31/2014)... 2014 Rogne Bioscience, a privately-held biotechnology company ... , has acquired a licence to anti-inflammatory peptides from ... potent anti-inflammatory activity of the peptides was discovered by ... Oxford,s Sir William Dunn School of Pathology. ... $1.5 million in seed financing, is developing a first-in-class, ...
(Date:7/31/2014)... San Francisco, California (PRWEB) July 31, 2014 ... expert systems that inform therapeutic decision-making in oncology, today ... on August 14, 2014 to discuss the Company's financial ... to provide an update about the business in the ... live audio call beginning on Thursday, August 14, 2014, ...
Breaking Biology Technology:Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4See-through organs and bodies will accelerate biomedical discoveries 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2
... (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing ... virus (HCV) infection, today announced that it will release ... 2008 on March 11,2008 at 7:00 a.m. EDT and ... results at 11:30 a.m. EDT on the same day., ...
... (Nasdaq,CM: INSM), a developer of follow-on biologics and biopharmaceuticals, today,reported results for ... and Recent Company Highlights, -- Follow-on Biologics Program ... Factor or G-CSF) ... products to enter clinical trials in 2008; ...
... Vical Incorporated,(Nasdaq: VICL ) today announced ... Officer, will participate in a roundtable discussion,"An Industry ... in,Global Health Product Development," and present an overview ... on Tuesday,March 11, at the Biotechnology Industry Organization ...
Cached Biology Technology:Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 3Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 4Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 5Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 6Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 7Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 8Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 9Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 10Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 11Vical to Present at BIO and BVGH Global Health Partnering Event 2Vical to Present at BIO and BVGH Global Health Partnering Event 3
(Date:7/31/2014)... beneath many of the roughly 156,000 gas stations ... corrosion in parts of underground gas storage tankscorrosion ... of groundwater, a source of drinking water. In ... reported many rapidly corroding gas storage tank components ... associated with use of gasoline-ethanol blends and the ...
(Date:7/31/2014)... protected 100 percent of animal models against the highly ... causes an intestinal disease that kills approximately 30,000 Americans ... Infection and Immunity . , In the ... against the purified toxins produced by C. difficile ... a laboratory model that mimics the human disease, after ...
(Date:7/31/2014)... An important step has been made to help better identify ... both an abnormal narrowing and enlarging of medium sized arteries ... kidneys and other organs causing damage. In a new report ... Journal , scientists provide evidence that that FMD may ... addition, they show a connection to abnormalities of bones and ...
Breaking Biology News(10 mins):NIST corrosion lab tests suggest need for underground gas tank retrofits 2C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... A method to detect contaminants in municipal water supplies ... Laboratory researchers whose findings are published on line in ... demonstrates that the technology that uses algae as sentinels ... Miguel Rodriguez Jr. and Elias Greenbaum of the Department ...
... Calif., August 27, 2009 -- Researchers at Burnham ... Southwestern Medical Center and University of Maryland have ... many bacteria can be targeted to kill dangerous ... can inhibit this enzyme and suppress the growth ...
... A new candidate gene for Specific Language Impairment has ... Rice at the University of Kansas, in collaboration with ... Gayn of Neocodex, Seville, Spain. The finding, reported in ... Disorders , was discovered by examining genes previously identified ...
Cached Biology News:ORNL scientists hone technique to safeguard water supplies 2The path to new antibiotics 2Researchers report gene associated with language, speech and reading disorders 2
... LUMIstar OPTIMA is a fully automated ... for the widest possible range of ... Reporter gene assays luciferase, -galactosidase, gene ... esters, dioxetanes..) Luminescent Immunoassays ...
... depleted sera are specifically depleted of a ... the depleted protein, the alternative and classical ... therefore ideal for the detection and quantitation ... have been used to assess complement activation ...
... The latest generation of the ... M.I.T. for the iontophoresis of neural ... (HRP) or tritiated amino acids into ... Stoelting. It may also be used ...
... In situ detection of apoptosis and ... event provides an early indication of the ... typically defined as a collapse in the ... measured by the change in the membrane ...
Biology Products: